Combined effects of soy isoflavone and lecithin on bone loss in ovariectomized mice
2
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
BACKGROUND/OBJECTIVES Isoflavones (ISFs) are effective in preventing bone loss, but not effective enough to prevent osteoporosis. Mixtures of soy ISF and lecithin (LCT) were prepared and characterized in an attempt to improve the bone loss. MATERIALS/METHODS The daidzein (DZ) and genistein (GN) solubility in soy ISF were measured using liquid chromatography-mass spectrometry. The change in the crystalline characteristics of soy ISF in LCT was evaluated using X-ray diffraction analysis. Pharmacokinetic studies were conducted to evaluate and compare ISF bioavailability. Animal studies with ovariectomized (OVX) mice were carried out to estimate the effects on bone loss. The Student's t-test was used to evaluate statistical significance. RESULTS The solubility of DZ and GN in LCT was 125.6 and 9.7 mg/L, respectively, which were approximately 25 and 7 times higher, respectively, than those in water. The bioavailability determined by the area under the curve of DZ for the oral administration (400 mg/kg) of soy ISF alone and the soy ISF-LCT mixture was 13.19 and 16.09 µg·h/mL, respectively. The bone mineral density of OVX mice given soy ISF-LCT mixtures at ISF doses of 60 and 100 mg/kg daily was 0.189 ± 0.020 and 0.194 ± 0.010 g/mm3, respectively, whereas that of mice given 100 mg/kg soy ISF was 0.172 ± 0.028 g/mm3. The number of osteoclasts per bone perimeter was reduced by the simultaneous administration of soy ISF and LCT. CONCLUSIONS The effect of preventing bone loss and osteoclast formation by ingesting soy ISF and LCT at the same time was superior to soy ISF alone as the bioavailability of ISF may have been improved by the emulsification and solvation of LCT. These results suggest the possibility of using the combination of soy ISF and LCT to prevent osteoporosis.
Abstract
BACKGROUND/OBJECTIVES Isoflavones (ISFs) are effective in preventing bone loss, but not effective enough to prevent osteoporosis. Mixtures of soy ISF and lecithin (LCT) were prepared and characterized in an attempt to improve the bone loss. MATERIALS/METHODS The daidzein (DZ) and genistein (GN) solubility in soy ISF were measured using liquid chromatography-mass spectrometry. The change in the crystalline characteristics of soy ISF in LCT was evaluated using X-ray diffraction analysis. Pharmacokinetic studies were conducted to evaluate and compare ISF bioavailability. Animal studies with ovariectomized (OVX) mice were carried out to estimate the effects on bone loss. The Student's t-test was used to evaluate statistical significance. RESULTS The solubility of DZ and GN in LCT was 125.6 and 9.7 mg/L, respectively, which were approximately 25 and 7 times higher, respectively, than those in water. The bioavailability determined by the area under the curve of DZ for the oral administration (400 mg/kg) of soy ISF alone and the soy ISF-LCT mixture was 13.19 and 16.09 µg·h/mL, respectively. The bone mineral density of OVX mice given soy ISF-LCT mixtures at ISF doses of 60 and 100 mg/kg daily was 0.189 ± 0.020 and 0.194 ± 0.010 g/mm3, respectively, whereas that of mice given 100 mg/kg soy ISF was 0.172 ± 0.028 g/mm3. The number of osteoclasts per bone perimeter was reduced by the simultaneous administration of soy ISF and LCT. CONCLUSIONS The effect of preventing bone loss and osteoclast formation by ingesting soy ISF and LCT at the same time was superior to soy ISF alone as the bioavailability of ISF may have been improved by the emulsification and solvation of LCT. These results suggest the possibility of using the combination of soy ISF and LCT to prevent osteoporosis.
참고문헌 (35)
- Akkawi I, "Osteoporosis : current concepts", Joints, 6, pp.122~127 (2018)
- Pisani P, "Major osteoporotic fragility fractures : risk factor updates and societal impact", World J Orthop, 7, pp.171~181 (2016)
- Sattui SE, "Fracture mortality : associations with epidemiology and osteoporosis treatment", Nat Rev Endocrinol, 10, pp.592~602 (2014)
- Ahlborg HG, "Bone loss and bone size after menopause", N Engl J Med, 349, pp.327~334 (2003)
- Väänänen HK, "Estrogen and bone metabolism", Maturitas, 23(Suppl), pp.S65~S69 (1996)
- Hedlund LR, "The effect of age and menopause on bone mineral density of the proximal femur", J Bone Miner Res, 4, pp.639~642 (1989)
- Chen X, "Isoflavones and bone : animal and human evidence of efficacy", J Musculoskelet Neuronal Interact, 2, pp.352~359 (2002)
- Picherit C, "Dose-dependent bone-sparing effects of dietary isoflavones in the ovariectomised rat", Br J Nutr, 85, pp.307~316 (2001)
- Min-Sun Kim, "Effects of Soy Isoflavone and", or Estrogen Treatments on Bone Metabolism in Ovariectomized Rats, 2005, pp.8(4), 439~445[DOI]
- 김대원, "Soy Isoflavones Mitigate Long-Term Femoral and Lumbar Vertebral Bone Loss in Middle-Aged Ovariectomized Mice", Journal of Medicinal Food, 12(3), pp.536~541 (2009), 한국식품영양과학회
- Xi Zheng, "Soy Isoflavones and Osteoporotic Bone Loss: A Review with an Emphasis on Modulation of Bone Remodeling", Journal of Medicinal Food, 19(1), pp.1~14 (2016), 한국식품영양과학회[DOI]
- Ma DF, "Soy isoflavone intake inhibits bone resorption and stimulates bone formation in menopausal women : meta-analysis of randomized controlled trials", Eur J Clin Nutr, 62, pp.155~161 (2008)
- Xiao Y, "Comprehensive evaluation of the role of soy and isoflavone supplementation in humans and animals over the past two decades", Phytother Res, 32, pp.384~394 (2018)
- Mei J, "High dietary phytoestrogen intake is associated with higher bone mineral density in postmenopausal but not premenopausal women", J Clin Endocrinol Metab, 86, pp.5217~5221 (2001)
- Ma DF, "Soy isoflavone intake increases bone mineral density in the spine of menopausal women : meta-analysis of randomized controlled trials", Clin Nutr, 27, pp.57~64 (2008)
- Taku K, "Effect of soy isoflavone extract supplements on bone mineral density in menopausal women : meta-analysis of randomized controlled trials", Asia Pac J Clin Nutr, 19, pp.33~42 (2010)
- 이한송이, "Effect of soy isoflavones supplement on climacteric symptoms, bone biomarkers, and quality of life in Korean postmenopausal women: a randomized clinical trial", Nutrition Research and Practice, 11(3), pp.223~231 (2017), 한국영양학회
- Kenny AM, "Soy proteins and isoflavones affect bone mineral density in older women : a randomized controlled trial", Am J Clin Nutr, 90, pp.234~242 (2009)
- Brink E, "Long-term consumption of isoflavone-enriched foods does not affect bone mineral density, bone metabolism, or hormonal status in early postmenopausal women : a randomized, double-blind, placebo controlled study", Am J Clin Nutr, 87, pp.761~770 (2008)
- 곽호석, "Marked Individual Variation in Isoflavone Metabolism After a Soy Challenge Can Modulate the Skeletal Effect of Isoflavones in Premenopausal Women", Journal of Korean Medical Science, 24(5), pp.867~873 (2009), 대한의학회
- Ward WE, "Soy isoflavones and fatty acids : effects on bone tissue postovariectomy in mice", Mol Nutr Food Res, 51, pp.824~831 (2007)
- Watkins BA, "Protective actions of soy isoflavones and n-3 PUFAs on bone mass in ovariectomized rats", J Nutr Biochem, 16, pp.479~488 (2005)
- Simopoulos AP, "Omega-3 fatty acids in inflammation and autoimmune diseases", J Am Coll Nutr, 21, pp.495~505 (2002)
- Watkins BA, "Omega-3 polyunsaturated fatty acids and skeletal health", Exp Biol Med(Maywood), 226, pp.485~497 (2001)
- Ciriminnaa R, "Enhancing and improving the extraction of omega-3 from fish oil", Sustain Chem Pharm, 5, pp.54~59 (2017)
- Goicoechea E, "Fate in digestion in vitro of several food components, including some toxic compounds coming from omega-3 and omega-6 lipids", Food Chem Toxicol, 49, pp.115~124 (2011)
- Ismail A, "Oxidation in EPA-and DHA-rich oils : an overview", Lipid Technol, 28, pp.55~59 (2016)
- Fricker G, "Phospholipids and lipid-based formulations in oral drug delivery", Pharm Res, 27, pp.1469~1486 (2010)
- Uchida R, "Combined effects of soy isoflavone and fish oil on ovariectomy-induced bone loss in mice", J Bone Miner Metab, 29, pp.404~413 (2011)
- Ihn HJ, "Fermented oyster extract prevents ovariectomy-induced bone loss and suppresses osteoclastogenesis", Nutrients, 11, pp.1392~1403 (2019)
- Jia L, "Polymorphs of daidzein and intermolecular interaction effect on solution crystallization", CrystEngComm, 19, pp.7146~7153 (2017)
- Zhang Z, "Daidzein-phospholipid complex loaded lipid nanocarriers improved oral absorption : in vitro characteristics and in vivo behavior in rats", Nanoscale, 3, pp.1780~1787 (2011)
- Lee SH, "Enhanced bioavailability of soy isoflavones by complexation with β-cyclodextrin in rats", Biosci Biotechnol Biochem, 71, pp.2927~2933 (2007)
- Deshpande AA, "Controlled-release drug delivery systems for prolonged gastric residence : an overview", Drug Dev Ind Pharm, 22, pp.531~539 (1996)
- Zhang Y, "Isoflavone reduces body weight by decreasing food intake in ovariectomized rats", Ann Nutr Metab, 54, pp.163~170 (2009)